In line with reduced survival, quantification of overall tumor burden showed that, at all time-points analyzed, re-expression of WT or mutant AIF resulted in increased lung tumor burden that was comparable to the Aif+/yKrasG12D cohorts (Fig. 6d, e; Supplementary information, Fig. S7d, e). The gene discussed is AIFM1; the disease is neoplasm.